Monitoring free serum IgE in severe asthma patients treated with omalizumab

Korn, Stephanie; Haasler, Ina; Fliedner, Florian; Becher, G; Strohner, Pavel; Staatz, Antonia; Taube, Christian; Buhl, Roland

doi:10.1016/j.rmed.2012.07.010

Cited by 60 publications

(31 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, administration of omalizumab generally increases serum IgE levels in patients with asthma [17]. Several reports have measured free IgE levels separately from omalizumab-bound IgE [18,19], but the studies concerned did not involve a clinical setting.…”

Section: Introductionmentioning

confidence: 99%

Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma

Mizuma

Tanaka

Uchida

et al. 2015

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, inhibits the binding of circulating IgE to mast cells and basophils, resulting in fewer episodes of airway inflammation, asthma symptoms and exacerbations in patients with severe allergic asthma. Treatment of patients with asthma using omalizumab increases serum total IgE (tIgE) levels. However, little is known about the influence of omalizumab on allergen-specific IgE (sIgE). Methods: tIgE and sIgE in 47 adult patients with severe asthma were measured with a fluorescent enzyme immunoassay (ImmunoCAP-FEIA) before and after omalizumab treatment. Results: Treatment with omalizumab increased tIgE and sIgE levels. The increases in sIgE by class category after omalizumab treatment were positively correlated with baseline sIgE positivity before treatment. The mean changes in sIgE levels after omalizumab treatment were also correlated with baseline sIgE levels before treatment. The mean changes in tIgE levels were positively correlated with the mean changes in IgE levels against Dermatophagoides pteronyssinus, crude house dust, Japanese cedar and moth. Omalizumab markedly influenced the negative-to-positive seroconversion rate for IgE against Japanese cedar (30.8%), Candida (29.0%) and moth (28.0%). Finally, all patients with negative-to-positive seroconversion for Japanese cedar-specific IgE had cedar pollinosis before beginning omalizumab treatment. Conclusions: The changes in sIgE levels after omalizumab treatment may be dependent on the baseline sIgE levels. Our data may indicate the presence of undetectable but functional sIgE.

show abstract

Section: Introductionmentioning

confidence: 99%

Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma

Mizuma

Tanaka

Uchida

et al. 2015

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…The available information from omalizumab‐treated asthma patients does not help to understand this observation. In one asthma patient, total IgE levels and free IgE levels did not change during omalizumab treatment, but the clinical response was good . Studies that evaluated free IgE levels in omalizumab‐treated asthma patients found no correlation with clinical response …”

Section: Discussionmentioning

confidence: 95%

The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change

Ertaş

Özyurt

Atasoy

et al. 2017

Allergy

177

116

View full text Add to dashboard Cite

show abstract

“…However, it is interestingly observed that the clinical results in patients receiving omalizumab treatment are not related with reduced IgE levels. This leads to contemplation regarding the other immunomodulator effects of omalizumab (7). Therefore, it is thought that the success of omalizumab in idiopathic anaphylaxis is enabled by reducing total IgE level, and especially by mast cell stabilization and reducing the number of FcεR receptors.…”

Section: Discussionmentioning

confidence: 99%

Omalizumab’s role in the treatment of steroid dependent malignant idiopathic anaphylaxis

2017

View full text Add to dashboard Cite

If an anaphylaxis episode is not caused by an identifiable trigger, it is defined as idiopathic anaphylaxis. Although it is rarely observed, idiopathic anaphylaxis is clinically significant because of its morbidity and fatality risk. No effective treatment has been demonstrated to date. We report a girl aged 16 years who had had malignant idiopathic anaphylaxis since the age of 12 years who was treated successfully with omalizumab. Although she avoided allergic trigger foods such as tomato and seafood, she used to have these attacks twice a week. Attacks were averted by taking 60 mg prednisone. When prednisone was tapered down to 5 mg on every alternate day, the episodes recurred. Later, attacks could not be controlled on <30 mg of prednisone daily. After being steroid-dependent for 4 years, subcutaneous omalizumab 225 mg every two weeks was started. Under omalizumab therapy, the attacks disappeared and prednisone was discontinued. (Turk Pediatri Ars 2017; 52: 105-7)

show abstract

Monitoring free serum IgE in severe asthma patients treated with omalizumab

Cited by 60 publications

References 32 publications

Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma

Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma

The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change

Omalizumab’s role in the treatment of steroid dependent malignant idiopathic anaphylaxis

Contact Info

Product

Resources

About